Chemotherapy for ovarian cancer during pregnancy: A systematic review and meta-analysis of case reports and series.
chemotherapy
efficacy
meta-analysis
ovarian cancer
pregnancy
Journal
The journal of obstetrics and gynaecology research
ISSN: 1447-0756
Titre abrégé: J Obstet Gynaecol Res
Pays: Australia
ID NLM: 9612761
Informations de publication
Date de publication:
Oct 2021
Oct 2021
Historique:
revised:
15
06
2021
received:
23
03
2021
accepted:
22
07
2021
pubmed:
4
8
2021
medline:
6
10
2021
entrez:
3
8
2021
Statut:
ppublish
Résumé
This study aims to investigate the safety and efficacy of chemotherapy in ovarian cancer patients in pregnancy. In this study, eligible studies were searched on PubMed, Embase, and Cochrane Library databases up to December 31, 2020. Data were calculated and presented by frequency and percentage, mean ± standard deviation (SD), and median (range), respectively. Kaplan-Meier survival analysis was performed to estimate overall survival (OS) and progression-free survival (PFS). Finally, 34 studies including 40 ovarian cancer cases receiving chemotherapy during pregnancy were included. All 40 patients received chemotherapy during pregnancy. During the follow-up, seven of 37 (18.9%) women had a relapse and four of them (4/7, 57.1%) died of recurrence. Survival analysis failed to reach median OS and PFS within the follow-up (range 3-72 months). Better OS and PFS after chemotherapy in pregnancy were obtained in women with early-stage ovarian cancer (I) compared with those with advanced stage (III-IV). Neither OS nor FS differed between women treated with multi-drugs and those with monotherapy. Forty-one newborns were delivered from 40 pregnant women. Thirty-four (34/41, 82.9%) were completely healthy at birth and the end of follow-up (range 0.18-160 months). However, one newborn died 5 days after birth due to multiple congenital malformations, and another one developed Tourette's syndrome, aphasia, Asperger's syndrome as well as speech delay. This meta-analysis first reveals the efficacy and safety of chemotherapy for ovarian cancer during pregnancy, especially for early-stage patients. Cisplatin or carboplatin is suggested to be used as monotherapy to reduce adverse effects.
Substances chimiques
Carboplatin
BG3F62OND5
Cisplatin
Q20Q21Q62J
Types de publication
Journal Article
Meta-Analysis
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3425-3436Subventions
Organisme : University of Chinese Academy of Sciences
Organisme : Research Foundation
Informations de copyright
© 2021 Japan Society of Obstetrics and Gynecology.
Références
Fruscio R, de Haan J, van Calsteren K, Verheecke M, Mhallem M, Amant F. Ovarian cancer in pregnancy. Best Pract Res Clin Obstet Gynaecol. 2017;41:108-17. https://doi.org/10.1016/j.bpobgyn.2016.09.013
van Calsteren K, Heyns L, de Smet F, van Eycken L, Gziri MM, van Gemert W, et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J Clin Oncol. 2010;28:683-9. https://doi.org/10.1200/JCO.2009.23.2801
Pereg D, Koren G, Lishner M. Cancer in pregnancy: gaps, challenges and solutions. Cancer Treat Rev. 2008;34:302-12. https://doi.org/10.1016/j.ctrv.2008.01.002
Boussios S, Moschetta M, Tatsi K, Tsiouris AK, Pavlidis N. A review on pregnancy complicated by ovarian epithelial and non-epithelial malignant tumors: diagnostic and therapeutic perspectives. J Adv Res. 2018;12:1-9. https://doi.org/10.1016/j.jare.2018.02.006
Grimm D, Woelber L, Trillsch F, Keller-v Amsberg G, Mahner S. Clinical management of epithelial ovarian cancer during pregnancy. Eur J Cancer. 2014;50:963-71. https://doi.org/10.1016/j.ejca.2013.12.020
Marret H, Lhomme C, Lecuru F, Canis M, Lévèque J, Golfier F, et al. Guidelines for the management of ovarian cancer during pregnancy. Eur J Obstet Gynecol Reprod Biol. 2010;149:18-21. https://doi.org/10.1016/j.ejogrb.2009.12.001
Korenaga TK, Tewari KS. Gynecologic cancer in pregnancy. Gynecol Oncol. 2020;157:799-809. https://doi.org/10.1016/j.ygyno.2020.03.015
Amant F, Berveiller P, Boere IA, Cardonick E, Fruscio R, Fumagalli M, et al. Gynecologic cancers in pregnancy: guidelines based on a third international consensus meeting. Ann Oncol. 2019;30:1601-12. https://doi.org/10.1093/annonc/mdz228
Zagouri F, Sergentanis TN, Chrysikos D, Filipits M, Bartsch R. Taxanes for ovarian cancer during pregnancy: a systematic review. Oncology. 2012;83:234-8. https://doi.org/10.1159/000341351
Cardonick E, Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol. 2004;5:283-91. https://doi.org/10.1016/S1470-2045(04)01466-4
Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;350:g7647. https://doi.org/10.1136/bmj.g7647
Luh L, Mahendra INB, Suwiyoga K, Budiana I, Mayura IM, Wiradnyana AP, et al. Management comprehensive multidisciplinary of malignant ovarian germ cell tumors and feto-maternal outcome: a case series report and literature review. Open Access Maced J Med Sci. 2019;7:1174-9. https://doi.org/10.3889/oamjms.2019.251
Xu T, Wang L, Jia Y, Jia Z, Li Z, Cui S, et al. Long-term multidisciplinary integrative therapy management resulted in favorable outcomes for ovarian cancer during pregnancy: a case report and literature review. J Ovarian Res. 2019;12:108. https://doi.org/10.1186/s13048-019-0584-3
Singhal SR, Chaudhary S, Agarwal K, Gupta A. Successful pregnancy outcome in recurrent ovarian cancer in a 26 year old: a case report. J Family Reprod Health. 2017;11:225-7.
Chen CH, Chiu LH, Chan C, Liu WM. Management of ovarian cancer in 14th gestational week of pregnancy by robotic approach with preservation of the fetus. Gynecol Obstet Invest. 2015;80:139-44. https://doi.org/10.1159/000368231
Ruiz Ramos J, Roma E, Palomar L, Poveda JL. Paclitaxel and carboplatin treatment for advanced ovarian cancer during pregnancy. Chemotherapy. 2013;59:344-5. https://doi.org/10.1159/000360691
Smith ER, Borowsky ME, Jain VD. Intraperitoneal chemotherapy in a pregnant woman with ovarian cancer. Obstet Gynecol. 2013;122(2 Pt 2):481-3. https://doi.org/10.1097/AOG.0b013e31828a845a
Cardonick E, Bhat A, Gilmandyar D, Somer R. Maternal and fetal outcomes of taxane chemotherapy in breast and ovarian cancer during pregnancy: case series and review of the literature. Ann Oncol. 2012;23:3016-23. https://doi.org/10.1093/annonc/mds170
Serkies K, Wegrzynowicz E, Jassem J. Paclitaxel and cisplatin chemotherapy for ovarian cancer during pregnancy: case report and review of the literature. Arch Gynecol Obstet. 2011;283(Suppl 1):97-100. https://doi.org/10.1007/s00404-011-1855-4
Barut A, Arikan I, Barut F, Harma M, Harma MI, Payasli B. Ovarian cancer during pregnancy. J Pak Med Assoc. 2011;61:914-6.
Benjapibal M, Chaopotong P, Leelaphatanadit C, Jaishuen A. Ruptured ovarian endodermal sinus tumor diagnosed during pregnancy: case report and review of the literature. J Obstet Gynaecol Res. 2010;36:1137-41. https://doi.org/10.1111/j.1447-0756.2010.01254.x
Doi D, Boh Y, Konishi H, Asakura H, Takeshita T. Combined chemotherapy with paclitaxel and carboplatin for mucinous cystadenocarcinoma of the ovary during pregnancy. Arch Gynecol Obstet. 2009;280:633-6. https://doi.org/10.1007/s00404-009-0950-2
Ghaemmaghami F, Abbasi F, Abadi AG. A favorable maternal and neonatal outcome following chemotherapy with etoposide, bleomycin, and cisplatin for management of grade 3 immature teratoma of the ovary. J Gynecol Oncol. 2009;20:257-9. https://doi.org/10.3802/jgo.2009.20.4.257
Rouzi AA, Sahly NN, Sahly NF, Alahwal MS. Cisplatinum and docetaxel for ovarian cancer in pregnancy. Arch Gynecol Obstet. 2009;280:823-5. https://doi.org/10.1007/s00404-009-0992-5
Tabata T, Nishiura K, Tanida K, Kondo E, Okugawa T, Sagawa N. Carboplatin chemotherapy in a pregnant patient with undifferentiated ovarian carcinoma: case report and review of the literature. Int J Gynecol Cancer. 2008;18:181-4. https://doi.org/10.1111/j.1525-1438.2007.00974.x
Karimi Zarchi M, Behtash N, Modares GM. Good pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for ovarian immature teratoma: a case report and literature review. Arch Gynecol Obstet. 2008;277:75-8. https://doi.org/10.1007/s00404-007-0416-3
Modares Gilani M, Karimi Zarchi M, Behtash N, Ghaemmaghami F, Mousavi AS, Behnamfar F. Preservation of pregnancy in a patient with advanced ovarian cancer at 20 weeks of gestation: case report and literature review. Int J Gynecol Cancer. 2007;17:1140-3. https://doi.org/10.1111/j.1525-1438.2007.00917.x
Hubalek M, Smekal-Schindelwig C, Zeimet AG, Sergi C, Brezinka C, Mueller-Holzner E, et al. Chemotherapeutic treatment of a pregnant patient with ovarian dysgerminoma. Arch Gynecol Obstet. 2007;276:179-83. https://doi.org/10.1007/s00404-007-0328-2
Motegi M, Takakura S, Takano H, Tanaka T, Ochiai K. Adjuvant chemotherapy in a pregnant woman with endodermal sinus tumor of the ovary. Obstet Gynecol. 2007;109(2 Pt 2):537-40. https://doi.org/10.1097/01.AOG.0000245450.62758.47
Robova H, Rob L, Hrehorcak M, Zoban P, Prusa R. Endodermal sinus tumor diagnosed in pregnancy: a case report. Int J Gynecol Cancer. 2007;17:914-6. https://doi.org/10.1111/j.1525-1438.2007.00850.x
Machado F, Vegas C, Leon J, Perez A, Sanchez R, Parrilla JJ, et al. Ovarian cancer during pregnancy: analysis of 15 cases. Gynecol Oncol. 2007;105:446-50. https://doi.org/10.1016/j.ygyno.2007.01.002
Ghaemmaghami F, Hasanzadeh M. Good fetal outcome of pregnancies with gynecologic cancer conditions: cases and literature review. Int J Gynecol Cancer. 2006;16(Suppl 1):225-30. https://doi.org/10.1111/j.1525-1438.2006.00510.x
Ferrandina G, Distefano M, Testa A, de Vincenzo R, Scambia G. Management of an advanced ovarian cancer at 15 weeks of gestation: case report and literature review. Gynecol Oncol. 2005;97:693-6. https://doi.org/10.1016/j.ygyno.2005.02.011
Han JY, Nava-Ocampo AA, Kim TJ, Shim JU, Park CT. Pregnancy outcome after prenatal exposure to bleomycin, etoposide and cisplatin for malignant ovarian germ cell tumors: report of 2 cases. Reprod Toxicol. 2005;19:557-61. https://doi.org/10.1016/j.reprotox.2004.11.002
Picone O, Lhommé C, Tournaire M, Pautier P, Camatte S, Vacher-Lavenue MC, et al. Preservation of pregnancy in a patient with a stage IIIB ovarian epithelial carcinoma diagnosed at 22 weeks of gestation and treated with initial chemotherapy: case report and literature review. Gynecol Oncol. 2004;94:600-4. https://doi.org/10.1016/j.ygyno.2004.05.030
Méndez LE, Mueller A, Salom E, González-Quintero VH. Paclitaxel and carboplatin chemotherapy administered during pregnancy for advanced epithelial ovarian cancer. Obstet Gynecol. 2003;102(5 Pt 2):1200-2.
Otton G, Higgins S, Phillips KA, Quinn M. A case of early-stage epithelial ovarian cancer in pregnancy. Int J Gynecol Cancer. 2001;11:413-7. https://doi.org/10.1046/j.1525-1438.2001.01047.x
Sood AK, Shahin MS, Sorosky JI. Paclitaxel and platinum chemotherapy for ovarian carcinoma during pregnancy. Gynecol Oncol. 2001;83:599-600. https://doi.org/10.1006/gyno.2001.6439
Markman M, Kulp B, Peterson G, Kennedy A. Weekly carboplatin as a strategy to prevent severe treatment-related emesis. Gynecol Oncol. 2000;78:265. https://doi.org/10.1006/gyno.2000.5870
Elit L, Bocking A, Kenyon C, Natale R. An endodermal sinus tumor diagnosed in pregnancy: case report and review of the literature. Gynecol Oncol. 1999;72:123-7. https://doi.org/10.1006/gyno.1998.5190
Henderson CE, Elia G, Garfinkel D, Poirier MC, Shamkhani H, Runowicz CD. Platinum chemotherapy during pregnancy for serous cystadenocarcinoma of the ovary. Gynecol Oncol. 1993;49:92-4. https://doi.org/10.1006/gyno.1993.1092
Christman JE, Teng NN, Lebovic GS, Sikic BI. Delivery of a normal infant following cisplatin, vinblastine, and bleomycin (PVB) chemotherapy for malignant teratoma of the ovary during pregnancy. Gynecol Oncol. 1990;37:292-5. https://doi.org/10.1016/0090-8258(90)90351-k
King LA, Nevin PC, Williams PP, Carson LF. Treatment of advanced epithelial ovarian carcinoma in pregnancy with cisplatin-based chemotherapy. Gynecol Oncol. 1991;41:78-80. https://doi.org/10.1016/0090-8258(91)90259-8
Kim DS, Park MI. Maternal and fetal survival following surgery and chemotherapy of endodermal sinus tumor of the ovary during pregnancy: a case report. Obstet Gynecol. 1989;73(3 Pt 2):503-7.
Malone JM, Gershenson DM, Creasy RK, Kavanagh JJ, Silva EG, Stringer CA. Endodermal sinus tumor of the ovary associated with pregnancy. Obstet Gynecol. 1986;68(3 Suppl):86S-9S.
Brucker MC, King TL. The 2015 US Food and Drug Administration pregnancy and lactation labeling rule. J Midwifery Womens Health. 2017;62:308-16. https://doi.org/10.1111/jmwh.12611
Horowitz NA, Henig I, Henig O, Benyamini N, Vidal L, Avivi I. Acute myeloid leukemia during pregnancy: a systematic review and meta-analysis. Leuk Lymphoma. 2018;59:610-6. https://doi.org/10.1080/10428194.2017.1347651
Mir O, Berveiller P, Goffinet F, Treluyer JM, Serreau R, Goldwasser F, et al. Taxanes for breast cancer during pregnancy: a systematic review. Ann Oncol. 2010;21:425-6. https://doi.org/10.1093/annonc/mdp517
Song Y, Liu Y, Lin M, Sheng B, Zhu X. Efficacy of neoadjuvant platinum-based chemotherapy during the second and third trimester of pregnancy in women with cervical cancer: an updated systematic review and meta-analysis. Drug Des Devel Ther. 2019;13:79-102. https://doi.org/10.2147/DDDT.S186966
Weisz B, Meirow D, Schiff E, Lishner M. Impact and treatment of cancer during pregnancy. Expert Rev Anticancer Ther. 2004;4:889-902. https://doi.org/10.1586/14737140.4.5.889
Azim HA Jr, Peccatori FA, Pavlidis N. Treatment of the pregnant mother with cancer: a systematic review on the use of cytotoxic, endocrine, targeted agents and immunotherapy during pregnancy. Part I: solid tumors. Cancer Treat Rev. 2010;36:101-9. https://doi.org/10.1016/j.ctrv.2009.11.007
Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160-70. https://doi.org/10.1093/annonc/mdt199
Luo H, Liu Y, Song Y, Hua Y, Zhu X. Aquaporin 1 affects pregnancy outcome and regulates aquaporin 8 and 9 expressions in the placenta. Cell Tissue Res. 2020;381:543-54. https://doi.org/10.1007/s00441-020-03221-w
Heinhuis KM, Ros W, Kok M, Steeghs N, Beijnen JH, Schellens JHM. Enhancing antitumor response by combining immune checkpoint inhibitors with chemotherapy in solid tumors. Ann Oncol. 2019;30:219-35. https://doi.org/10.1093/annonc/mdy551
Colombo N, Sessa C, du Bois A, Ledermann J, McCluggage W, McNeish I, et al. ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent diseasedagger. Ann Oncol. 2019;30:672-705. https://doi.org/10.1093/annonc/mdz062
Abdul Razak AR, Li L, Bryant A, Diaz-Padilla I. Chemotherapy for malignant germ cell ovarian cancer in adult patients with early stage, advanced and recurrent disease. Cochrane Database Syst Rev. 2011;3:CD007584. https://doi.org/10.1002/14651858.CD007584.pub2
Roett MA, Evans P. Ovarian cancer: an overview. Am Fam Physician. 2009;80:609-16.
Torre LA, Trabert B, DeSantis CE, Miller KD, Samimi G, Runowicz CD, et al. Ovarian cancer statistics, 2018. CA Cancer J Clin. 2018;68:284-96. https://doi.org/10.3322/caac.21456
Uccello M, Boussios S, Samartzis EP, Moschetta M. Systemic anti-cancer treatment in malignant ovarian germ cell tumours (MOGCTs): current management and promising approaches. Ann Transl Med. 2020;8:1713. https://doi.org/10.21037/atm.2020.04.15
Richter T, Janoudi G, Amegatse W, Nester-Parr S. Characteristics of drugs for ultra-rare diseases versus drugs for other rare diseases in HTA submissions made to the CADTH CDR. Orphanet J Rare Dis. 2018;13:15. https://doi.org/10.1186/s13023-018-0762-1
Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, Malfettone A, Pérez-García J, Llombart-Cussac A, et al. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019;14:230. https://doi.org/10.1186/s13023-019-1202-6
Nissen T, Wynn R. The clinical case report: a review of its merits and limitations. BMC Res Notes. 2014;7:264. https://doi.org/10.1186/1756-0500-7-264